This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Take a closer look at your untreated squamous PD-L1 negative mNSCLC patients: Meet Bob

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Could KEYTRUDA® (pembrolizumab) in combination with chemotherapy transform treatment expectations for your untreated squamous PD-L1 metastatic non small cell lung cancer patients?*

Take a closer look at how KEYTRUDA in combination with chemotherapy could help your patients in the downloadable patient profile below.

Download Bob's profile: 62-year old male with stage IV squamous NSCLC, negative for EGFR and ALK mutations; PD-L1 non-expressor, no liver or brain metastases at diagnosis. Current smoker with a 25 pack-year history.

Find out more information about KEYTRUDA® (pembrolizumab) in metastatic NSCLC:

Click here


*KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.1
KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults.1

Reference

  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01609 | Date of Preparation: June 2021